))
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Manage episode 417556943 series 3381434
Indhold leveret af ReachMD. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af ReachMD eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
CME credits: 1.00
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/integrating-clinical-insights-key-ggej-cancer-data-analyzed-from-the-san-diego-oncology-conference/24471/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
…
continue reading
Valid until: 05-02-2025
Claim your CME credit at https://reachmd.com/programs/cme/integrating-clinical-insights-key-ggej-cancer-data-analyzed-from-the-san-diego-oncology-conference/24471/
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
666 episoder
Del
